Efforts to target amyloid protein plaques, thought to be responsible for Alzheimer’s disease, have run into trouble © Science Photo Library
The world needs to tackle head-on the market failures undermining dementia research and drug development, UK Prime Minister David Cameron told a summit of world health and finance leaders in London in June. He announced an investigation into how to get medicines to patients earlier, extend patents and facilitate research collaborations, to report this autumn. But just how much difference will these sorts of measures make when scientists are still grappling with exactly what causes different types of dementia?
‘Ticking time bomb’ of global neurodegenerative disease burden will be difficult to defuse